Fewer than one in 10 patients eligible to benefit from GLP-1 drugs such as Wegovy have access to them, caution the WHO as it issues its first guidance on the medications.
Given in excess of 1,000,000,000 individuals worldwide currently obese, it is calling for increased and just access to this class of drugs.
Based on projections, in excess of 2,000,000,000 are projected to be obese by 2030 without intervention.
"The new guidelines acknowledges that obesity is a long-term condition that can be managed with holistic and continuous treatment," stated its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and supply-chain constraints are significant barriers to broad availability to the treatments that can help people shift significant weight, notes the organization.
Skinny Jab Shortage
Despite the current most optimistic case, the production of these medications might only reach around 100 million people – fewer than 10% of the global need, according to the WHO.
The guideline urges governments and firms to expand access, through approaches like licensing agreements.
A patent on the active ingredient – the core ingredient of a leading brand – is due to expire in a number of nations in 2026.
The Way Weight-Loss Jabs Function
GLP-1 drugs replicate a biological compound to delay gastric emptying, curb appetite and increase the sense of being full so users eat less.
People typically see weight reduction after several weeks of beginning the weekly injections.
Evidence indicates users may regain a significant portion after a year of stopping the drug, when their normal hunger come back.
To be overweight or obese raises your chance for contracting health problems, including type 2 diabetes, cardiovascular issues, brain attack, and some malignancies.
Obesity impacts people in every country and was linked to millions of fatalities worldwide in 2024, according to the WHO.
